RCS - Angle PLC - Parsortix based PD-L1 assay showcased at AACR

AngleAnnouncement

15/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241115:nRSO3444Ma&default-theme=true

RNS Number : 3444M  Angle PLC  15 November 2024

 For immediate release  15 November 2024

 

ANGLE plc ("the Company")

 

parsortix-based pd-l1 assay showcased at international liquid biopsy
conference

 

CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer
patients and may help to advance personalised treatment

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce the publication of
new data at the American Association for Cancer Research (AACR) Special
Conference in Cancer Research, Liquid Biopsy: From Discovery to Clinical
Implementation, in San Diego, US from 13 to 16 November 2024.

 

ANGLE is presenting a poster entitled "Investigating PD-L1 status in
circulating tumor cells isolated from the blood samples of lung cancer
patients". The poster presentation reports on ANGLE's immunofluorescence assay
for the identification of different CTC phenotypes (epithelial, mesenchymal
and those transitioning) and the determination of Programmed Death Ligand-1
(PD-L1) status. Analytical verification demonstrated that the assay
successfully produced linear data with high analytical sensitivity(1) and
specificity(2) for epithelial, mesenchymal, blood lineage and PD-L1 markers.

 

PD-L1 allows cancer cells to evade the host immune response when upregulated,
and assessment of PD-L1 status in tumour tissue can indicate if immunotherapy
has the potential to be an effective treatment. However, lung tissue biopsies
can be challenging and expensive and are not always successful, plus PD-L1
status in tumour tissue can become outdated during tumour evolution and may
not be representative of metastatic sites. ANGLE has developed a liquid biopsy
assay that allows for minimally invasive, longitudinal monitoring of PD-L1
status in CTCs harvested using the Parsortix(®) system.

 

The assay identified CTCs in 91% (29/32) of metastatic lung cancer patients
assessed as part of an ongoing longitudinal study, presenting with a range of
phenotypes. PD-L1 positive CTCs were observed in 72% of patients with a PD-L1
positive tissue biopsy and in 27% of patients with a PD-L1 negative tissue
biopsy, demonstrating the potential for improved assessment of tumour
heterogeneity through analysis of PD-L1 status in CTCs.

 

A patient case study revealed that CTC PD-L1 status varied between blood
draws, showing discordance with the initial tumour biopsy at multiple time
points. The results presented in this study demonstrate the potential for the
development of CTC-based dynamic PD-L1 testing to advance personalised
treatment for metastatic lung cancer patients.

 

Chief Scientific Officer, Karen Miller, commented:

"We are pleased to have presented this poster at the AACR Special Conference
in Cancer Research. The results of this study further demonstrate the utility
of ANGLE's PD-L1 assay. Longitudinal monitoring is essential to the
advancement of personalised medicine, and we look forward to contributing to
this advancement and supporting the needs of our pharma customers through
development of our CTC-based assays."

 

The poster is available for review at: https://angleplc.com/resources/posters/
(https://angleplc.com/resources/posters/)

 

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

For Research Use Only. Not for use in diagnostic procedures.

 

1.   Analytical sensitivity = proportion of harvested cells known to express
the marker(s) of interest which were marker positive in the assay.

 

2.   Analytical specificity = proportion of harvested cells known to NOT
express the marker(s) of interest which were marker negative in the assay.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
CTC harvesting technology known as the Parsortix(®) PC1 System enables
complete downstream analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on clinical services and diagnostic
products. The clinical services business is offered through ANGLE's
GCLP-compliant laboratories. Services include custom made assay development
and clinical trial testing for pharma. Products include the Parsortix system,
associated consumables and assays.

 

Over 100 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

 

Any reference to regulatory authorisations such as FDA clearance, CE marking
or UK MHRA registration shall be read in conjunction with the full intended
use of the product:

 

The Parsortix(®) PC1 system is an in vitro diagnostic device intended to
enrich circulating tumor cells (CTCs) from peripheral blood collected in
K(2)EDTA tubes from patients diagnosed with metastatic breast cancer.  The
system employs a microfluidic chamber (a Parsortix cell separation cassette)
to capture cells of a certain size and deformability from the population of
cells present in blood.  The cells retained in the cassette are harvested by
the Parsortix PC1 system for use in subsequent downstream assays.  The end
user is responsible for the validation of any downstream assay.  The
standalone device, as indicated, does not identify, enumerate or characterize
CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs,
including monitoring indications or as an aid in any disease management and/or
treatment decisions.

 

All results reported in this announcement and any other products and services
are for research use only and not for use in diagnostic procedures.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRALZLLFZFLEFBZ